Haematopoietic stem cell transplantation to treat aplastic anaemia

Bibliography

• ISSARAGRISIL S, SRIRATANASATAVORN C, PIANKIJAGUM A et al.: Incidence of aplastic anemia in Bangkok. The Aplastic Anemia Study Group. Blood (1991) 77:2166–2168.
   Google Scholar
• DELGADO-LLAMAS JL, LOPEZ-KARPOVITCH X, MARIN-LOPEZ A et al.: Low-doses of high potency antithymocyte globulin (ATG) in severe aplastic anemia. Experience with the Mexican ATG. Acta Haematol. (1989) 81:70–74.
   PubMed Web of Science ®Google Scholar
• DAVIES SM, WALKER DJ: Aplastic anaemia in the Northern Region 1971-1978 and follow-up of long term survivors. Clin. Lab. Haematol. (1986) 8:307–313.
   PubMedGoogle Scholar
• YOUNG NS, MACIEJEWSKI J: The pathophysiology of acquired aplastic anemia. N EngL J. Med. (1997) 336:1365–1372.
   PubMed Web of Science ®Google Scholar
• •Excellent position paper regarding the current understanding of mechanisms of autoimmunity leading to acquired AA.
   Google Scholar
• BACIGALUPO A, CHAPLE M, HOWS J et al.: Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (Mpred) with or without androgens: a randomized trial from the EBMT SAA Working Party. Br. J. Haematol. (1993) 83:145–151.
   PubMed Web of Science ®Google Scholar
• CAMITTA BM, THOMAS ED, NATHAN DG et aL: Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 48:63–70.
   PubMed Web of Science ®Google Scholar
• •Classic paper showing the preponderance that PBSCT would have in treating SAA patients during the following decades.
   Google Scholar
• BACIGALUPO A, HOWS J, GLUCKMAN E et al.: Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br. J. Haematol. (1988) 70:177–182.
   PubMed Web of Science ®Google Scholar
• FRICKHOFEN N, HEIMPEL H, KALTWASSER JP et aL: Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood (2003) 101:1236–1242.
   PubMed Web of Science ®Google Scholar
• SCHREZENMEIER H, MARIN P, RAGHAVACHAR A et aL: Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br. J. Haematol. (1993) 85:371–377.
   PubMed Web of Science ®Google Scholar
• KILLICK SB, MARSH JC: Aplastic anemia:management. Blood Rev. (2000) 14:157–171.
   PubMed Web of Science ®Google Scholar
• BACIGALUPO A. BRUNO B, SARACCO P et aL: Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EMBT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti de Midolio Osseo (GITMO). Blood (2000) 95:1931–1934.
   Google Scholar
• MARSH JC, BALL SE, DARBYSHIRE P et al.: Guidelines for the diagnosis and management of acquired aplastic anaemia. Br. J. Haematol. (2003) 123:782–801.
   PubMed Web of Science ®Google Scholar
• ••Excellent review and guidelines fromEngland on current aspects of the disease.
   Google Scholar
• BACIGALUPO A, BRAND R, ONETO R et al.: Treatment of acquired severe aplastic anaemia: bone marrow transplantation compared with immunosuppressive therapy - the European Group for Blood and Marrow transplantation experience. Semin. HematoL (2000) 37:69–80.
   PubMed Web of Science ®Google Scholar
• STORB R, LEISENNING W, ANASETTI Get al.: Long term follow up of allogeneic marrow transplants in patients with aplastic anaemia conditioned with cyclophosphamide with antithymocyte globulin. Blood (1997) 89:3890–3901.
   Google Scholar
• ••Excellent perspective of long-term resultsof transplantation in AA.
   Google Scholar
• RUIZ-ARGOELLES GJ, GOMEZ-RANGEL D: Long term results of the immunosuppressive treatment of patients with severe, acquired aplastic anemia: a single institution study. Acta Haematol. (2003) 110:184–187.
   PubMed Web of Science ®Google Scholar
• MCSWEENEY PA, NIEDERWIESER D, SHIZURU A et al.: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 97:3390–3400.
   PubMed Web of Science ®Google Scholar
• DEEG HJ, SEIDEL K, CASPER J et al.: Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol. Blood Marrow liwnspL (1999) 5:243–252.
   PubMedGoogle Scholar
• KOJIMA S, INABA J, YOSHIMI A et al.:Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br. J. HaematoL (2001) 114:706–711.
   PubMed Web of Science ®Google Scholar
• VASSILIOU GS, WEBB DK, PAMPHILON D et al.: Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br. J. HaematoL (2001) 114:701–705.
   PubMed Web of Science ®Google Scholar
• •A provocative study. New conditioning regimen using alternative donors.
   Google Scholar
• BARON F, STORB R, LITTLE M: Hematopoietic stem cell transplantation: five decades of progress. Arch. Med. Res. (2003) 34:528–544.
   PubMed Web of Science ®Google Scholar
• HERRERA-GARZA JL, JAIME-PEREZ JC, IBARRA-PEART R, MONTEMAYOR JL, GOMEZ-ALMAGUER D: High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anemia patients without anti-thymocyte globulin in the conditioning regimen. Bone Marrow lianspL (1999) 24:845–848.
   PubMed Web of Science ®Google Scholar
• •One of the first papers demonstrating the feasibility of PBSCT for SAA and the importance of infusing high numbers of haematopoietic cells to circumvent the problem of alloimmunisation to HLA antigens.
   Google Scholar
• MIN CK, KIM DW, LEE JW, HAN CW, MIN WS, KIM CC: Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. Haematologica (2000) 86:303–310.
   Google Scholar
• •Stem cell dose importance is highlighted in this very interesting study.
   Google Scholar
• HELDAL D, TJONNFJORD G, BRINCH Let al.: A randomized study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow lianspL (2000) 25:1129–1136.
   Google Scholar
• STOREK J, DAWSON MA, STORER B et al.: Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 97:3380–3389.
   PubMed Web of Science ®Google Scholar
• ABRAHAMSEN IW, SOMME S, HELDAL D, EGELAND T, KVALE D, TJONNFJORD GE: Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host-disease. Haematologica (2005) 90:86–93.
   PubMed Web of Science ®Google Scholar
• BITTENCOURT H, ROCHA V CHEVRET S et al.: Association of CD-34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood (2002) 99:2726–2733.
   Google Scholar
• KORBLING M, ANDERLINI P: Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood (2001) 98:2900–2908.
   PubMed Web of Science ®Google Scholar
• WEAVER CH, LONGIN K, BUCKNER CD, BENSINGER W: Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow TranspL (1994) 13:411–415.
   PubMed Web of Science ®Google Scholar
• MAJOLINO I, SAGLIO G, SCIME R et al.: High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow TranspL (1996) 17:555–560.
   PubMed Web of Science ®Google Scholar
• •This article underscores the finding of a higher risk when infusing peripheral stem cells instead of bone marrow-derived progenitors.
   Google Scholar
• PAVLETIC SZ, SMITH LM, BISHOP MR et al.: Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am. J. HematoL (2005) 78:265–274.
   PubMed Web of Science ®Google Scholar
• GRATWOHL A, SCHMID O, BALDOMERO H, HORISBERGER B, URBANO-ISPIZUA A: Accreditation Committee of the European Group for Blood and Marrow Transplantation. Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow ThanspL (2004) 34:855–875.
   Google Scholar
• ••Depicts the current status of multiplefactors affecting HSCT.
   Google Scholar
• WALL DA: Allogeneic peripheral blood versus bone marrow transplantation: children are small adults and more. J. Clin. OncoL (2004) 22:4865–4866.
   PubMed Web of Science ®Google Scholar
• KROGER N, ZANDER AR: Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk. Lymphoma (2002) 43:1391–1394.
   PubMed Web of Science ®Google Scholar
• EAPEN M, HOROWITZ MM, KLEIN JP et al.: Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J. Clin. OncoL (2004) 22:4872–80.
   PubMed Web of Science ®Google Scholar
• ••Excellent study analysing the different outcomes observed in younger patients when PBSC are used instead of bone marrow.
   Google Scholar
• KOJIMA S, HORIBE K, INABA J et al.:Long-term outcome of acquired aplastic anaemia in children: Comparison between immunosuppressive therapy and bone marrow transplantation. Br. J. HaematoL (2000) 111:321–328.
   PubMed Web of Science ®Google Scholar
• EAPEN M, RAMSAY MK, MERTENS AC, ROBINSON LL, DEFOR T, DAVIES SA: Late outcomes after bone marrow transplant for aplastic anemia. Br. J. HaematoL (2000) 111:754–760.
   PubMed Web of Science ®Google Scholar
• STORB R, ETZIONI R, ANASETTI, C et al.: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood (1994) 84:941–949.
   PubMed Web of Science ®Google Scholar
• LOCASCIULLI A, BRUNO B, RAMBALDI A: Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. Haematologica (2004) 89:1054–1061.
   PubMed Web of Science ®Google Scholar
• •Interesting study aimed at defining the contribution of G-CSF to haematopoietic recovery as complement of 1ST for SAA.
   Google Scholar
• KARANES C, CONFER D, WALKER T, ASKREN A, KELLER C: Unrelated donor stem cell transplantation: the role of the National Marrow Donor Program. Oncology (Huntingt.) (2003) 17:1036–1038.
   PubMedGoogle Scholar
• BACIGALUPO A, ONETO R, BRUNO B et al.: Current status of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow Transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta HaematoL (2000) 103:19–25.
   Google Scholar
• ••Excellent overview of transplant activity inEurope and its perspectives.
   Google Scholar
• HANDGRETINER R, KLINGEBIEL T, LANG P, GORDON P, NIETHAMMER D: Megadose transplantation of highly purified haploidentical stem cells: current results and future prospects. Pediatr. Transpl. (2003) 7:51–55.
   PubMed Web of Science ®Google Scholar
• BENESCH M, URBAN C, SYKORA KW et al.: Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anemia. Br. J. HaematoL (2004) 125:58–63.
   PubMed Web of Science ®Google Scholar
• BUNIN N, APLENC R, IANNONE R et al.: Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion. Bone Marrow TranspL (2005) 35:369–373.
   PubMed Web of Science ®Google Scholar
• ••Very good report of initial results ofUR-SCT.
   Google Scholar
• MUDUR G: Indian researchers accused of violating ethical guidelines. Br. Med. J. (2005) 330:60.
   PubMedGoogle Scholar
• COHEN Y, NAGLER A: Hematopoietic stem cell transplantation using umbilical cord blood. Leuk. Lymphoma (2003) 44:1287–1299.
   PubMed Web of Science ®Google Scholar
• YU LC, WALL DA, SANDLER E, CHAN KW, GRAYSON G, KLETZEL M: Unrelated cord blood transplant experience by the pediatric blood and marrow transplant consortium. Pediatr. HematoL OncoL (2001) 18:235–245.
   PubMed Web of Science ®Google Scholar
• MAO P, WANG S, WANG S et al.: Umbilical cord blood transplant for adult patients with severe aplastic anemia using anti-lymphocyte globulin and cyclophosphamide as conditioning regimen. Bone Marrow TranspL (2004) 33:33–38.
   PubMed Web of Science ®Google Scholar
• •This paper was one of the first to show that a reasonable good result can be obtained when transplanting adult patients with SAA employing URJCB-SCT.
   Google Scholar
• STORB R, BLUME KG, O'DONELL MR et al.: Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol. Blood Marrow TranspL (2001) 7:39–44.
   Google Scholar
• STORB R, PRENTICE RL, THOMAS ED et al.: Marrow transplantation for treatment of aplastic anemia: an analysis of factors associated with graft rejection. N Engl. J. Med. (1977) 296:61–66.
   PubMed Web of Science ®Google Scholar
• LOCATELLI F, BRUNO B, ZECCA M et al.: Cyclosporin A and short term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from HLA identical siblings: result of a GITMO/ EBMT randomized trial. Blood (2000) 96:1690–1697.
   PubMed Web of Science ®Google Scholar
• GLUCKMAN E, HOROWITZ MM, CHAMPLIN RE et al.: Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease regimens on outcome. Blood (1992) 79:269–275.
   PubMed Web of Science ®Google Scholar
• REMBERGER M, BEELEN DW, FAUSER A, BASARA N, BASU O, RINGDEN O: Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood (2005) 105:548–551.
   PubMed Web of Science ®Google Scholar
• NIEDERWIESER D, PEPE M, STORB R et al.: Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anemia. Br. J. Haematol. (1988) 69:23–28.
   PubMed Web of Science ®Google Scholar
• STORB R, LONGTON G, ANASETTI C et al.: Changing trends in marrow transplantation for aplastic anemia. Bone Marrow TranspL (1992) 10:45–52.
   PubMed Web of Science ®Google Scholar
• HINTERBERGER W, ROWLINGS PA, HINTERBERGER-FISCHER M et aL: Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann. Intern. Med. (1997) 126:116–122.
   PubMed Web of Science ®Google Scholar
• WAGNER JL, DEEG HJ, SEIDEL K et al.:Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives: an update of the Seattle experience. Transplantation (1996) 61:54–61.
   PubMed Web of Science ®Google Scholar
• TZENG CH, CHEN PM, FANS et al.: CY/TBI-800 as a pretransplant regimen for allogeneic bone barrow transplantation for severe aplastic anemia using HLA-haploidentical family donors. Bone Marrow lianspL (1996) 18:273–277.
   PubMed Web of Science ®Google Scholar
• DEEG HJ, AMYLON ID, HARRRIS RE et al.: Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol. Blood Marrow TranspL (2001) 7:208–215.
   PubMed Web of Science ®Google Scholar
• KOJIMA S, MATSUYAMA T, KATO S et al.: Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood (2002) 100:799–803.
   PubMed Web of Science ®Google Scholar
• LAUGHLIN MJ, BARKER J, BAMBACH B et al.: Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J. Med. (2001) 344:1815–1822.
   PubMed Web of Science ®Google Scholar
• BARR RD: The importance of lowering costs of stem cell transplantation in developing countries. Int. J. Hematol (2002) 76\(Suppl. 1):365–367.
   Google Scholar
• GOMEZ-ALMAGUER D, VELA-OJEDA J, JAIME-PEREZ JC et al.: Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. Am. J. Hematol (2005) (In Press).
   Google Scholar
• CHAMPLIN R, PEREZE WS, PASSWEG J et al.: Addition of antithymocyte globulin (ATG) to cyclophosphamide (Cy) for HLA-identical allogeneic bone marrow transplantation (BMT) for severe aplastic anemia (SAA). Result of a randomized controlled trial (abstract). Blood (2003) 102:269.
   Google Scholar
• CHAN KW, LI CK, WORTH LL et al: A fluciarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transpl (2001) 27:125–128.
   PubMed Web of Science ®Google Scholar
• GUPTA V BALL SE, SAGE D et al: Marrow transplants from matched unrelated donors for aplastic anemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transpl (2005) 35:467–471.
   PubMed Web of Science ®Google Scholar
• DULLEY FL, VIGORITO AC, ARANHA FJ et al: Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transpl (2004) 33:9–13.
   PubMed Web of Science ®Google Scholar
• DEVETTEN MP, VOSE JM: Graft-versus-host disease: how to translate new insights into new therapeutic strategies. Biol. Blood Marrow Transpl (2004) 10:815–825.
   PubMed Web of Science ®Google Scholar
• ••Excellent state of the art paper.
   Google Scholar
• RUIZ-ARGOELLES GJ, GOMEZ-ALMAGUER D: Breaking dogmata to help patients: non-myeloablative hematopoietic stem cell transplantation. Expert Opin. Biol. Ther. (2004) 4:1693–1699.
   PubMed Web of Science ®Google Scholar
• COURIEL DR, SALIBA RM, GIRALT S et al: Acute and chronic graft versus-host-disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol. Blood Marrow Transpl. (2004) 10:178–185.
   PubMed Web of Science ®Google Scholar
• VELA-OJEDA J, GARCIA-RUIZ ESPARZA MA, TRIPP-VILLANUEVA F: Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia. Stem Cells Dev. (2004) 13:571–579.
   PubMed Web of Science ®Google Scholar
• DEEG HJ, LEISERING W, STORB R et al.: Long- term outcome after marrow transplantation for severe aplastic anemia. Blood (1998) 10:3637–3645.
   Google Scholar
• ATKINSON K, HOROWITZ MM, GALE RP et al.: Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 75:2459–2464.
   PubMed Web of Science ®Google Scholar
• GOMEZ-ALMAGUER D: The simplification of SCT in developing countries has resulted in cost-lowering and availability to more patients. Int. J. Hematol (2002) 76\(Suppl. 1):380–382.
   Google Scholar
• RUIZ-ARGUELLES GJ: Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int. J. Hematol (2002) 76\(Suppl. 1):376–379.
   Google Scholar
• MACIEJEWSKI JP, HIBBS JR, ANDERSON S, KATEVAS P, YOUNG NS: Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp. Hematol (1994) 22:1102–1110.
   PubMed Web of Science ®Google Scholar
• MACIEJEWSKI J, SELLERI C, SATO T, ANDERSON S, YOUNG NS: Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br. J. Haematol. (1995) 91:245–252.
   PubMed Web of Science ®Google Scholar
• RISITANO AM, MACIEJEWSKI JP, GREEN S, PLASILOVA M, ZENG W YOUNG NS: In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet (2004) 364:355-364. Excellent perspective paper on the molecular mechanisms involved in AA.
   Google Scholar
• NISSEN C, SCHUBERT J: Seeing thegood and bad in aplastic anemia: is autoimmunity in AA dysregulated or antineoplastic? Hematol J. (2002) 3:169–175.
   Google Scholar
• ••Provocative hypothesis on an alternative role of autoimmunity in AA.
   Google Scholar